IL-18 production inhibitor

A Ganoderma chinensis extract-based anti-inflammatory agent addresses the limitations of existing agents by enabling mass production and effective cytokine suppression, providing cost-effective relief from inflammatory diseases.

JP7588388B2Active Publication Date: 2024-11-22MCB CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2018182494
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2018-09-27
Publication Date
2024-11-22
Estimated Expiration
2038-09-27

AI Technical Summary

Technical Problem

Existing anti-inflammatory agents derived from heterotrophic organisms like Aurantiochytrium and region-specific algae are not suitable for mass production, leading to high costs and limited availability.

Method used

An anti-inflammatory agent containing an extract from Ganoderma chinensis, specifically from its leaves and stems, which can be easily cultivated and processed into various forms such as tablets, powders, granules, liquids, gels, capsules, or creams, utilizing methods like solvent extraction and nano-formation to enhance production efficiency.

Benefits of technology

The Ganoderma chinensis extract effectively suppresses inflammatory cytokines, offering significant anti-inflammatory effects and reducing manufacturing costs through scalable cultivation and processing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588388000001
    Figure 0007588388000001
  • Figure 0007588388000002
    Figure 0007588388000002
  • Figure 0007588388000003
    Figure 0007588388000003
Patent Text Reader

Abstract

To provide an antiinflammatory agent containing the natural materials that permit mass production.SOLUTION: An antiinflammatory agent has extract from Momordica charantia as an active ingredient.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an anti-inflammatory agent containing an extract from Momordica charantia. [Background technology]

[0002] Today, Japan has entered into an unprecedented super-aging society, and the incidence of malignant neoplasms (cancer) among the elderly is steadily increasing year by year.

[0003] Anticancer drugs are commonly administered as a treatment for various cancers. However, this therapy is accompanied by severe side effects such as headache, nausea, stomatitis, and diarrhea, and alleviating these side effects has been an issue.

[0004] Many of the side effects caused by the administration of anticancer drugs are inflammatory diseases mediated by inflammatory cytokines.

[0005] Inflammatory cytokines are substances produced by lymphocytes and macrophages and are involved in inflammatory responses associated with bacterial or viral infections, tumors, and tissue damage. Examples of cytokines include tumor necrosis factor (TNF-α), interleukin (IL)-1α, IL-1β, IL-2, IL-6, IL-8, IL-12A, IL-18, monocyte chemotactic protein-1 (MCP-1), and interferon (IFN)-γ.

[0006] Suppressing the expression of these inflammatory cytokines can be extremely beneficial in preventing, treating, and ameliorating the above-mentioned side effects.

[0007] As anti-inflammatory agents that suppress the expression of inflammatory cytokines, artificially synthesized ones such as anakinra are well known, but substances derived from natural products that suppress the expression of inflammatory cytokines have also been reported. For example, Patent Document 1 reports an anti-inflammatory agent that contains an extract of Aurantiochytrium, a type of algae, as an active ingredient. Patent Document 2 also discloses a composition that contains an extract of Sargassum umbellata, another type of algae, as an active ingredient. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] JP 2017-137265 A [Patent Document 2] Special Publication No. 2018-516986 Summary of the Invention [Problem to be solved by the invention]

[0009] The Aurantiochytrium in Patent Document 1 is a heterotrophic organism and is therefore not suitable for mass production. Also, the Paragonimus umbellata in Patent Document 2 is an algae that is ubiquitous in certain regions and is also not suitable for mass production.

[0010] Therefore, an object of the present invention is to provide an anti-inflammatory agent containing a substance derived from a natural product that can be mass-produced. [Means for solving the problem]

[0011] The inventors of the present application have discovered that an extract from momordica charantia suppresses the expression of inflammatory cytokines, and have thus completed the present invention.

[0012] That is, the present invention provides a first anti-inflammatory agent comprising: Contains an extract from momordica charantia as the active ingredient Provided is an anti-inflammatory agent.

[0013] The present invention also relates to a second anti-inflammatory agent, which is a first anti-inflammatory agent, The extract is from only the leaves and stems of the momordica charantia. Provided is an anti-inflammatory agent.

[0014] The present invention also relates to a third anti-inflammatory agent, which is a first or second anti-inflammatory agent, In the form of tablets, powders, granules, liquids, gels, capsules or creams Provided is an anti-inflammatory agent. Effect of the Invention

[0015] The anti-inflammatory agent of the present invention contains an extract from Momordica charantia as an active ingredient, and thus the anti-inflammatory agent of the present invention can exert an anti-inflammatory effect since the extract from Momordica charantia suppresses the expression of inflammatory cytokines.

[0016] In addition, momordica charantia, which is the raw material of the anti-inflammatory agent of the present invention, can be easily cultivated anywhere above ground, has a fast growth rate, and can produce a large amount of leaves and stems, which allows the anti-inflammatory agent of the present invention to be mass-produced while reducing production costs. [Brief description of the drawings]

[0017] [Figure 1] FIG. 1 is a flow chart showing an example of a process for producing an anti-inflammatory agent according to an embodiment of the present invention. [Diagram 2] FIG. 1 is a graph comparing the amounts of TNF-α mRNA in control test 1, control test 2, and addition test. [Diagram 3] FIG. 1 is a graph comparing the amount of IL-1α mRNA in control test 1, control test 2, and addition test. [Figure 4] FIG. 1 is a graph comparing the amount of IL-8 mRNA in control test 1, control test 2, and addition test. [Diagram 5] FIG. 1 is a graph comparing the amount of IL-12A mRNA in control test 1, control test 2, and addition test. [Figure 6] FIG. 1 is a graph comparing the amount of IL-18 mRNA in control test 1, control test 2, and addition test. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] The anti-inflammatory agent of the present embodiment contains an extract from momordica charantia as an active ingredient. More specifically, the anti-inflammatory agent of the present embodiment contains an extract from only the leaves and stems of momordica charantia as an active ingredient. The main components of this extract are momordicin, charantin, and corosolic acid, but other components may be included. In addition, other plants of the genus Momordica (i.e., Momordica), such as momordica chinensis, cucurbita quinata, and cacrol, may be used as the raw material for the anti-inflammatory agent of the present invention. In addition, the leaves and stems of momordica charantia, which are the raw materials for the anti-inflammatory agent of the present embodiment, may be collected from momordica grown with buds, or may be collected from momordica grown without buds. However, in momordica charantia grown without buds, the active ingredients can be concentrated in the leaves and stems, so leaves and stems harvested from momordica charantia grown without buds are more preferable as the raw material for the anti-inflammatory agent of the present invention.

[0019] The anti-inflammatory agent of the present embodiment is in the form of a tablet, powder, granule, liquid, gel, capsule, or cream, which allows the anti-inflammatory agent of the present invention to be not only orally ingested but also directly applied to the skin.

[0020] With reference to FIG. 1, the anti-inflammatory agent of the present embodiment is produced as follows.

[0021] 1, the anti-inflammatory agent of the present embodiment is produced through step 1 (cultivation step), step 2 (harvesting step), step 3 (extraction step), and step 4 (separation step). In other words, the production process of the anti-inflammatory agent of the present embodiment includes a cultivation step, a harvesting step, an extraction step, and a separation step.

[0022] First, a cultivation process is carried out in which momordica charantia is cultivated according to a conventional method until buds appear on the vine, the buds are removed from the vine, and cultivation is continued. This allows the active ingredients of momordica charantia to be concentrated in the leaves and stems. In order to concentrate as many active ingredients as possible in the leaves and stems, it is preferable to perform the bud removal treatment as soon as possible after buds appear, and it is preferable to perform the treatment on all buds that have appeared. In particular, it is preferable to perform the bud removal treatment before the length of the buds that have appeared reaches 1 cm. It is to be noted that the present invention is not limited to this, and buds may be suppressed by administering a plant hormone or controlling the temperature.

[0023] After the cultivation step, the leaves and stems of the grown momordica charantia are harvested and dried to be used as the raw material for the anti-inflammatory agent of the present embodiment, in the harvesting step. The method for harvesting the momordica charantia leaves and stems is not particularly limited, but hand-picking is preferred.

[0024] After the harvesting step, an extraction step is performed in which an extract is collected from the leaves and stems of the harvested bitter melon. Specifically, a pressing method in which an extract is obtained by crushing the raw material with a roller or a centrifuge, a steam distillation method in which an extract is obtained by exposing the crushed raw material to heated steam, and a solvent extraction method in which an extract is obtained by dissolving the raw material in a predetermined solvent can be appropriately used. Here, the above pressing method and solvent extraction method are preferred from the viewpoint of avoiding thermal decomposition of the extract, and the solvent extraction method is more preferred in order to reduce the load caused by pressing.

[0025] More specifically, the extraction step of the present embodiment includes a crushing step and a soaking step, that is, in the extraction step of the present embodiment, the crushing step and the soaking step are carried out in this order.

[0026] In the crushing step, the collected leaves and stems are cut into pieces of appropriate size and then crushed by a crusher. The collected leaves and stems may be dried before crushing. As the crusher, a physical crushing device such as various mills, mortars, homogenizers, ultrasonic treatment, etc. may be used, or a chemical crushing method may be used using an enzyme that decomposes cell walls, such as cellulase or pectinase. In addition, crushing by a freeze crushing method is more preferable because it can minimize the outflow of active ingredients during the crushing process. By carrying out this crushing step, the raw leaves and stems are adjusted to a particle size of several μm to several hundred μm.

[0027] After the grinding step, the ground raw material is immersed in a suitable solvent to perform the immersion step. The solvent used in this immersion step can be water or various organic solvents. In addition, the water used as the solvent in this step is preferably in a state in which impurities such as salts and residual chlorine have been removed. For example, pure water such as distilled water, RO water (water passed through a reverse osmosis membrane), and deionized water (water from which metal ions and the like have been removed by ion exchange resins and the like) is preferable. In addition, examples of organic solvents used as the solvent in this step include monohydric or polyhydric alcohols, ethers, esters, aromatic hydrocarbons, and the like. For example, in consideration of ease of handling and availability, ethanol, propylene glycol (PG), dipropylene glycol (DPG), ethylene glycol (EG), polyethylene glycol (PEG), 1,3-butylene glycol (BG), glycerin, and the like are preferable.

[0028] In this soaking step, when water is used as the solvent, the extraction time can be shortened by heating the solution to 100°C. In addition, when an organic solvent is used as the solvent in this soaking step, the heating temperature can be determined taking into consideration the boiling point of the solvent. In addition, by stirring the solution during the heating, more components can be eluted, and therefore the recovery rate of the extract can be improved. For stirring, a rotary blade mixer or a magnetic stirrer with a heat plate that can perform heating and stirring can be used, but stirring with a stirring rod while heating can also be used.

[0029] Depending on the production amount of the anti-inflammatory agent, etc., the above-mentioned soaking step may use Soxhlet extraction, accelerated solvent extraction (ASE), ultrasonic extraction, microwave extraction, high pressure liquid extraction (PLE), supercritical fluid extraction (SFE), etc.

[0030] However, the present invention is not limited thereto, and the extraction step may further include a nanoization step. That is, the extraction step may be performed in sequence of a pulverization step, a nanoization step, and a soaking step. More specifically, in this nanoization step, after the pulverization step, the raw material leaves and stems are further refined until the particle size is several nm to several hundred nm. This maximizes the surface area of ​​the raw material leaves and stems, and increases the amount of extraction. In addition, this nanoization step can use ultra-high pressure wet atomization method, supersonic droplet collision method, laser ablation method, etc., but the nanoization method is not limited thereto. In addition, for anti-inflammatory agents having a dosage form of cream or solid agent, this nanoization step can be omitted.

[0031] After the extraction step is performed, a separation step is performed in which the liquid portion containing the extract and the solvent (hereinafter referred to as the "raw extract") is separated from the residual portion of the leaves and stems to obtain only the raw extract. Specific separation methods may include natural filtration, pressure filtration, or vacuum filtration using a filter, or separation using a centrifuge. When the solvent used in the extraction step is not used as it is as a solvent for the anti-inflammatory agent, a solvent separation step may be performed in which the solvent is further separated from the raw extract. Examples of this solvent separation step include, but are not limited to, a method in which, when the solvent used is water, water is evaporated by gentle heating, and when the solvent used is an organic solvent, the solvent is separated by using another solvent in which only the organic solvent can dissolve.

[0032] The above-mentioned extract stock solution may contain other components. For example, polyphenols, amino acids, minerals, etc. may be added. That is, the above-mentioned extraction process may further include an addition process of adding polyphenols, amino acids, minerals, etc. As the polyphenols to be added, flavonoids (catechin, anthocyanin, tannin, rutin, isoflavone) are preferable from the viewpoint of sterilization and antibacterial properties of the skin, and anthocyanins having an antioxidant effect on sebum are more preferable. When anthocyanins are extracted from natural products, the natural products may be subjected to the above-mentioned nanoization process to extract the anthocyanins. In addition, if necessary, a natural product from which anthocyanins are to be extracted (for example, flowers, etc.) may be mixed with leaves and stems of momordica charantia, and then crushed to carry out a nanoization process, so that components of momordica charantia and anthocyanins can be extracted simultaneously. The amino acids to be added may be any essential amino acids. The minerals to be added may be the main mineral elements sodium, magnesium, phosphorus, sulfur, chlorine, potassium, and calcium, as well as zinc, copper, manganese, iodine, etc. Furthermore, if necessary, plant-derived extracts such as jojoba seed oil, seaweed-derived extracts, mineral-derived extracts, animal-derived extracts, blood circulation promoting components, nutritional supplement components such as vitamins, moisturizing components, fragrances, preservatives, etc. may be added.

[0033] The extract stock solution obtained in the above separation step is mixed with an appropriate amount of water and a thickener and stirred to obtain a gel- or cream-like anti-inflammatory agent. The extract stock solution obtained in the above separation step is also appropriately diluted and concentrated with a solvent such as water or ethanol to obtain a liquid anti-inflammatory agent.

[0034] After carrying out the above separation process, the extract liquid is dried to volatilize the solvent in the solution and obtain a residue, which is then subjected to a drying process.

[0035] The residue obtained in this drying step is mixed with appropriate amounts of whey calcium, hardened rapeseed oil, crystalline cellulose, silicon dioxide and biotin, and molded in a molding machine to obtain a tablet-shaped anti-inflammatory agent.

[0036] The residue obtained in this drying step is treated in a conventional manner to obtain an anti-inflammatory agent in the form of a powder, granules or capsules.

[0037] Examples of the present invention and evaluation of the anti-inflammatory effect will be described below, but the present invention is not limited to the following examples.

[0038] (Collection and drying of raw materials) Leaves and stems of bitter melon plants that had been cultivated for 50 days after germination and had undergone bud removal treatment were harvested and dried until the moisture content reached 6% by weight.

[0039] (Preparation of extract stock solution) 50 g of dried leaves and stems were crushed, and then the crushed leaves and stems were immersed in 500 mL of purified water (Japanese Pharmacopoeia), heated while stirring with a magnetic stirrer equipped with a heat plate, and boiled at 100° C. for 30 minutes. Then, the mixture was centrifuged at 10,000 rpm for 15 minutes, and the supernatant was collected to obtain an extract stock solution (Example).

[0040] (Test method for anti-inflammatory effect) To evaluate the anti-inflammatory effect of the obtained extract stock solution (Example), an inflammatory cytokine expression analysis test was carried out. This inflammatory cytokine expression analysis test consisted of an addition test, a control test 1, and a control test 2. The addition test, the control test 1, and the control test 2 were carried out as follows.

[0041] 3×10 human monocyte THP-1 cells were placed in a 48-well plate. 5 The cells were seeded at a concentration of 0.3 ml / well, and Phorbol 12-Myristate 13-Acetate (PMA) was added at the same time to a final concentration of 0.5 μg / ml. At the same time, the extract stock solution (Example) obtained in the above step was added at a predetermined final concentration, and the cells were cultured in a CO2 incubator (5% CO2, 37°C) for 4 days. After that, the medium was replaced with a lipopolysaccharide (LPS: final concentration 1 μg / ml)-containing medium containing a predetermined concentration of the extract stock solution (Example), and the cells were cultured for 24 hours. After the culture was completed, total RNA was collected from each cell and cDNA was prepared using a Fastlane Cell RT-PCR Kit (Qiagen), and the amount of mRNA of inflammatory cytokines (tumor necrosis factor (TNF-α), interleukin (IL)-1α, IL-8, IL-12A, and IL-18) was quantified by real-time PCR to obtain the results of the addition test.

[0042] In addition, the above-mentioned addition test was carried out under the same conditions except that the extract stock solution (Example) and LPS were not used, and the results were recorded as Control Test 1. Furthermore, the above-mentioned addition test was carried out under the same conditions except that the extract stock solution (Example) was not used, and the results were recorded as Control Test 2.

[0043] A Student's t-test was performed on the measurement results of the additive test and the control test 2, and a significance level (P) of less than 5% was determined to be statistically significant. In Figures 2 to 6, P<0.05 is indicated with *, P<0.01 with **, and P<0.001 with ***.

[0044] (Test results and evaluation of anti-inflammatory effects) 2 to 6 show the mRNA amounts (n=3, mean ± standard error) of inflammatory cytokines (TNF-α, IL-1α, IL-8, IL-12A, and IL-18) in control test 1, control test 2, and addition test. From FIGS. 2 to 6, it was confirmed that the mRNA amounts of inflammatory cytokines in the addition test using the extract stock solution (Example) and LPS were significantly lower than the mRNA amounts of inflammatory cytokines in control test 2 not using the extract stock solution (Example). In other words, it was revealed that the extract stock solution (Example) significantly suppresses the production of inflammatory cytokines (TNF-α, IL-1α, IL-8, IL-12A, and IL-18) induced by LPS.

[0045] From these results, it can be understood that an anti-inflammatory agent containing an extract from Momordica charantia as an active ingredient exhibits excellent anti-inflammatory effects.

[0046] (Preparation of cream-type anti-inflammatory agent) The obtained extract stock solution was mixed with a thickener (hydroxypropylmethylcellulose) in a weight ratio of extract stock solution:thickener=1:49 to prepare a cream-type anti-inflammatory agent.

[0047] (Preparation of liquid anti-inflammatory agent) 20 g of ethanol was added to 5 g of the obtained extract stock solution to obtain an ethanol diluted solution, which was then concentrated 30 times to prepare a liquid anti-inflammatory agent.

[0048] (Preparation of anti-inflammatory agent in tablet form) The obtained extract was dried to evaporate the solvent in the solution, and a residue was obtained. The obtained residue was mixed with whey calcium, hardened rapeseed oil, crystalline cellulose, silicon dioxide and biotin in appropriate amounts, and molded in a molding machine to prepare a tablet-shaped anti-inflammatory agent.

[0049] (Test results and evaluation of tablet-type anti-inflammatory drugs) The tablet-shaped anti-inflammatory agent of the present embodiment obtained by the above-mentioned manufacturing method was administered to four subjects (A, B, C, D) who were receiving anti-cancer drugs, and the alleviation of side effects caused by the administration of anti-cancer drugs, i.e., the anti-inflammatory effect, was confirmed. The results and evaluation are shown below.

[0050] A tablet-type anti-inflammatory agent of the present embodiment was administered to subject A (66 years old) suffering from pancreatic cancer and metastatic liver cancer (stage 4b) three times a day (before breakfast, lunch, and dinner), and the alleviation of side effects of the anti-cancer drugs was observed. The anti-cancer drugs administered to subject A were Abraxane and Gemcitabine, and the side effects caused by the administration of the anti-cancer drugs were the development of ulcers in the duodenum caused by Helicobacter pylori, nausea, dizziness, loss of appetite, hair loss, fever, pale complexion, fatigue, lethargy, taste disorder, smell disorder, diarrhea, and stomatitis. After administration of the tablet-type anti-inflammatory agent of the present embodiment, the symptoms of the above side effects, nausea, dizziness, loss of appetite, hair loss, fever, pale complexion, fatigue, lethargy, taste disorder, smell disorder, diarrhea, and stomatitis, did not appear.

[0051] Subject B (60 years old) suffering from colon cancer (stage 3b) in the rectum was administered the tablet-type anti-inflammatory agent of this embodiment three times a day (before breakfast, lunch, and dinner), and the alleviation of side effects of the anti-cancer drug was observed. The anti-cancer drugs administered to subject B were oxaliplatin and Xeloda tablets, and the side effects caused by the administration of the anti-cancer drugs were suppuration of the stoma attachment site, discomfort in the throat, peripheral nerve disorder, vascular pain, nausea, dizziness, loss of appetite, hair loss, fever, deterioration of complexion, fatigue, lethargy, taste disorder, smell disorder, diarrhea, and stomatitis. After administration of the tablet-type anti-inflammatory agent of this embodiment, none of the above side effects, such as nausea, dizziness, loss of appetite, hair loss, fever, deterioration of complexion, fatigue, lethargy, taste disorder, smell disorder, diarrhea, and stomatitis, appeared.

[0052] The tablet-type anti-inflammatory agent of this embodiment was administered to subject C (50 years old) suffering from breast cancer (stage 4b) three times a day (before breakfast, lunch, and dinner), and the state of alleviation of the side effects of the anticancer drug was observed. The anticancer drugs administered to subject C were navelbine tartrate and a hormone drug, and the side effects caused by the administration of the anticancer drug were mild hair loss, hair loss, nausea, dizziness, loss of appetite, fever, pale complexion, fatigue, lethargy, taste disorder, smell disorder, diarrhea, and stomatitis. After administration of the tablet-type anti-inflammatory agent of this embodiment, the symptoms of the above side effects, hair loss, nausea, dizziness, loss of appetite, fever, pale complexion, fatigue, lethargy, taste disorder, smell disorder, diarrhea, and stomatitis, did not appear.

[0053] Subject D (63 years old) suffering from gastric cancer (stage 4a: cancer metastasis to the liver, peritoneum and gallbladder) was administered the tablet-type anti-inflammatory agent of this embodiment three times a day (before breakfast, lunch and dinner) and observed for alleviation of side effects of the anticancer drug. The anticancer drug administered to the subject was Gleevec tablets, and side effects caused by the administration of the anticancer drug included digestive symptoms such as hypoglycemia, nausea, vomiting and diarrhea, skin symptoms such as edema, rash and itching, muscle pain and cramps, liver dysfunction, anemia, fatigue, malaise, fever, taste disorder, smell disorder, loss of appetite, diarrhea and stomatitis. After administration of the tablet-form anti-inflammatory agent of this embodiment, among the above-mentioned side effects, none of the following symptoms appeared: digestive symptoms such as nausea, vomiting, and diarrhea; skin symptoms such as edema, rash, and itching; muscle pain and convulsions; liver dysfunction, anemia, fatigue, lethargy, fever, taste disorder, smell disorder, loss of appetite, diarrhea, and stomatitis.

[0054] The anti-inflammatory agent of the present embodiment is effective against cytokine-mediated inflammatory diseases caused by anticancer drugs used in the treatment of malignant neoplasms (cancer), but the present invention is not limited thereto. That is, the anti-inflammatory agent of the present invention is also effective in alleviating inflammatory diseases caused by the overproduction of inflammatory cytokines, systemic inflammatory response syndrome, collagen diseases such as chronic rheumatoid arthritis, allergic diseases, arteriosclerosis, restenosis after percutaneous transluminal angioplasty, insulin resistance, metabolic diseases such as diabetes, and multiple sclerosis, graft-versus-host disease, viral hepatitis, HIV infection, and other infectious diseases.

Claims

1. Contains an extract from momordica charantia as the active ingredient An inhibitor of IL-18 production.

2. The IL-18 production inhibitor according to claim 1, The extract is from only the leaves and stems of the momordica charantia. An inhibitor of IL-18 production.

3. The IL-18 production inhibitor according to claim 1 or 2, In the form of tablets, powders, granules, liquids, gels, capsules or creams An inhibitor of IL-18 production.

Citation Information

Patent Citations

  • External preparation for skin for ameliorating cytotoxicity of active oxygen species

    JP2008184439A

  • Inflammatory disease therapeutic agent and use thereof

    JP2017137265A

  • A composition for preventing or treating arthritis containing an extract of Sargassum chinensis as an active ingredient

    JP2018516986A